In the subanalysis including only the IBD patients (3706 patients contributing 10,332 person-years of follow-up), the pooled incidence of new or recurrent cancer in patients receiving IMM was 37.9 per 1000 p-y, without statistical difference with the other groups of treatments (no immunosuppressants or anti-TNFα). Here, TNF is linked to inflammatory bowel disease.